Skip to main content
Clinical Trials/EUCTR2009-012203-26-EE
EUCTR2009-012203-26-EE
Active, not recruiting
Phase 1

Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia - NEUROSIS

niversitätsklinikum Tübingen0 sites863 target enrollmentApril 26, 2010

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
High risk of bronchopulmonary dysplasia in very preterm neonates
Sponsor
niversitätsklinikum Tübingen
Enrollment
863
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 26, 2010
End Date
July 31, 2016
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
niversitätsklinikum Tübingen

Eligibility Criteria

Inclusion Criteria

  • Entry criteria involve a gestational age of 23 0/7\- 27 6/7 weeks, a postnatal age \< 12 hours, the necessity for any form of positive pressure support (mechanical or nasal ventilation or CPAP), singleton or second born in case of multiple pregnancy and parental consent for participation.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) no
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Exclusion criteria involve a clinical decision not to administer therapies (infant not considered viable), dysmorphic features or congenital malformations that adversely affect life expectancy or neurodevelopment and known or suspected congenital heart disease (not including a persistent ductus arteriosus and/or an atrial septum defect).

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia - NEUROSIS
EUCTR2009-012203-26-DEniversity Children's Hospital, Department of Neonatology850
Active, not recruiting
Phase 1
Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary DysplasiaSurvival of extremely Low Birth Weight (ELBW) infants has improved in recent decades but Bronchopulmonary Dysplasia (BPD) remains a major health care problem. BPD is a chronic lung disease that occurs in premature infants requiring mechanical ventilation and oxygen therapy, but also develops in preterm neonates who require little or no ventilatory or oxygen supportMedDRA version: 14.1Level: PTClassification code 10006475Term: Bronchopulmonary dysplasiaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2009-012203-26-BEniversity Children’s Hospital, Department of Neonatology850
Active, not recruiting
Phase 1
Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia - NEUROSIS
EUCTR2009-012203-26-NLniversity Children's Hospital, Department of Neonatology850
Active, not recruiting
Phase 1
eonatal European Study of Inhaled SteroidsRisk of Bronchopulmonary Dysplasia at Very Preterm InfantsMedDRA version: 14.1Level: PTClassification code 10006475Term: Bronchopulmonary dysplasiaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2009-012203-26-GRniversity Children's Hospital, Department of Neonatology863
Active, not recruiting
Phase 1
Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia - NEUROSIS
EUCTR2009-012203-26-CZniversity Children's Hospital, Department of Neonatology863